drugset / Trial / NCT01671787

A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B

NCT01671787

Phase 1 Completed 51 enrolled Gilead Sciences
RandomizedParallel-groupOpen-labelTreatment

Summary

This is an open-label study evaluating multiple doses of GS-7340 versus Tenofovir disoproxil fumarate (TDF).

Timeline

Start
2012-03
Primary completion
2013-04
Completion
2013-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenofovir disoproxil fumarate Small molecule 300 mg
Subject tenofovir alafenamide Small molecule 8 mg
Subject tenofovir alafenamide Small molecule 25 mg
Subject tenofovir alafenamide Small molecule 40 mg
Subject tenofovir alafenamide Small molecule 120 mg